Effects of using dexamethasone with dexmedetomidine as adjuvants to local anesthetic mixture in adductor canal block combine with Local infiltration analgesia for total knee arthroplasty : Randomized controlled trial

Effects of using dexamethasone with dexmedetomidine as adjuvants to local anesthetic mixture in adductor canal block combine with local infiltration analgesia for total knee arthroplasty: Randomized controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250710003

Enrollment

Registered

2025-07-10

Start date

2021-07-07

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative pain management in total knee arthroplasty (TKA) patients. This study focuses on optimizing pain control strategies following TKA surgery, aiming to enhance patient recovery, reduce opioid consumption, and minimize adverse effects related to pain management interventions. Total knee arthroplasty Postoperative pain management Adductor canal block Dexmedetomidine Regional anesthesia

Interventions

Patients will receive an adductor canal block with 15 mL of 0.375% bupivacaine (AstraZeneca, Bangkok, Thailand), mixed with 4 mg dexamethasone (1 mL) (General Drugs House, Bangkok, Thailand) and dexme

Experimental Drug,Active Comparator Drug

Dexamethasone and Dexmedetomidine Group,Control Group

Eligibility

Sex/Gender

All

Age

45 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age between 45 and 75 years 2. ASA physical status I to III 3. BMI between 18 and 35 or BW more than 50 kg 4. Undergoing first-time, unilateral total knee arthroplasty as an elective procedure

Exclusion criteria

Exclusion criteria: 1. Contraindications for spinal anesthesia 2. Allergy to any components of the periarticular analgesic injection, including bupivacaine and ketorolac 3. Allergy to any medications used in the study, including dexmedetomidine, acetaminophen, dexamethasone, sulfa drugs, and celecoxib 4. Revision TKA or bilateral TKA 5. Chronic knee pain unrelated to osteoarthritis 6. History of continuous opioid use for 3 or more months, except in cases of long-term cessation and not classified as chronic pain conditions 7. Pre-existing numbness in the operated knee 8. Other types of inflammatory arthritis 9. Psychiatric disorders 10. History of ischemic heart disease or coronary artery bypass surgery 11. History of gastrointestinal ulcers, gastrointestinal bleeding, or bleeding disorders 12. Pregnant or breastfeeding women 13. Impaired renal function with glomerular filtration rate less than 30 ml per min 14. Preoperative heart rate less than 50 bpm or cardiac arrhythmia confirmed by preoperative ECG 15. History of ischemic or hemorrhagic stroke 16. History of abnormal bleeding disorders

Design outcomes

Primary

Measure	Time frame
Numerical Rating Scale (NRS) 0, 4, 6, 12, 24, 48, 72 H postoperative NRS	—

Secondary

Measure	Time frame
Opioid side effects Postoperative day 0-3 Nausea, Vomiting, Sedation scores,Morphine Consumption Postoperative 24, 48 H mg,Orthopedic Outcome Score Postoperative 24, 48 H Maximum Active Flexion of Knee, Straight Leg Raising Time, Time to Up and Go (TUG) Test	—

Countries

Thailand

Contacts

Public ContactSithee Chumthong

Faculty of Medicine, Vajira Hospital, Navamindradhiraj University

nuesithee@gmail.com022443266

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026